204 related articles for article (PubMed ID: 35220832)
1. Recent advances in targeted drug delivery for the treatment of pancreatic ductal adenocarcinoma.
Song H; Jiang C
Expert Opin Drug Deliv; 2022 Mar; 19(3):281-301. PubMed ID: 35220832
[TBL] [Abstract][Full Text] [Related]
2. Gradient tumor microenvironment-promoted penetrating micelles for hypoxia relief and immunosuppression reversion in pancreatic cancer treatment.
Luo Y; Li C; Zhang Y; Liu P; Chen H; Zhao Z; Wang Y; Zhou Z; Song H; Su B; Li C; Li X; Zhang T; You H; Wu Y; Tian Z; Zhang S; Guo Y; Fan H; Chen Q; Jiang C; Sun T
Acta Biomater; 2023 Sep; 167():387-400. PubMed ID: 37276955
[TBL] [Abstract][Full Text] [Related]
3. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts.
Liu H; Shi Y; Qian F
Adv Drug Deliv Rev; 2021 May; 172():37-51. PubMed ID: 33705881
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
5. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment.
Tarannum M; Vivero-Escoto JL
Adv Drug Deliv Rev; 2022 Aug; 187():114357. PubMed ID: 35605679
[TBL] [Abstract][Full Text] [Related]
6. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
[TBL] [Abstract][Full Text] [Related]
7. Recent Advances in Well-Designed Therapeutic Nanosystems for the Pancreatic Ductal Adenocarcinoma Treatment Dilemma.
Yang XY; Lu YF; Xu JX; Du YZ; Yu RS
Molecules; 2023 Feb; 28(3):. PubMed ID: 36771172
[TBL] [Abstract][Full Text] [Related]
8. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
[TBL] [Abstract][Full Text] [Related]
9. Nanomedicine and epigenetics: New alliances to increase the odds in pancreatic cancer survival.
Urbanova M; Cihova M; Buocikova V; Slopovsky J; Dubovan P; Pindak D; Tomas M; García-Bermejo L; Rodríguez-Garrote M; Earl J; Kohl Y; Kataki A; Dusinska M; Sainz B; Smolkova B; Gabelova A
Biomed Pharmacother; 2023 Sep; 165():115179. PubMed ID: 37481927
[TBL] [Abstract][Full Text] [Related]
10. Exploring the potential of exosomes in diagnosis and drug delivery for pancreatic ductal adenocarcinoma.
Xu B; Chen Y; Peng M; Zheng JH; Zuo C
Int J Cancer; 2023 Jan; 152(2):110-122. PubMed ID: 35765844
[TBL] [Abstract][Full Text] [Related]
11. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
12. The Paradoxical Web of Pancreatic Cancer Tumor Microenvironment.
Lafaro KJ; Melstrom LG
Am J Pathol; 2019 Jan; 189(1):44-57. PubMed ID: 30558722
[TBL] [Abstract][Full Text] [Related]
13. Nanodiamond Mediated Molecular Targeting in Pancreatic Ductal Adenocarcinoma: Disrupting the Tumor-stromal Cross-talk, Next Hope on the Horizon?
Singh M; Pal P; Dutta RS; Marbaniang D; Ray S; Mazumder B
Curr Cancer Drug Targets; 2023; 23(8):620-633. PubMed ID: 36843367
[TBL] [Abstract][Full Text] [Related]
14. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future.
Christenson ES; Jaffee E; Azad NS
Lancet Oncol; 2020 Mar; 21(3):e135-e145. PubMed ID: 32135117
[TBL] [Abstract][Full Text] [Related]
15. Novel systemic treatment approaches for metastatic pancreatic cancer.
Dorman K; Heinemann V; Kobold S; von Bergwelt-Baildon M; Boeck S
Expert Opin Investig Drugs; 2022 Mar; 31(3):249-262. PubMed ID: 35114868
[TBL] [Abstract][Full Text] [Related]
16. Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma.
Al Haddad AH; Adrian TE
Expert Opin Investig Drugs; 2014 Nov; 23(11):1499-515. PubMed ID: 25078674
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppression, immune escape, and immunotherapy in pancreatic cancer: focused on the tumor microenvironment.
Zhu YH; Zheng JH; Jia QY; Duan ZH; Yao HF; Yang J; Sun YW; Jiang SH; Liu DJ; Huo YM
Cell Oncol (Dordr); 2023 Feb; 46(1):17-48. PubMed ID: 36367669
[TBL] [Abstract][Full Text] [Related]
18. Targeting Aggressive Fibroblasts to Enhance the Treatment of Pancreatic Cancer.
Yu Y; Schuck K; Friess H; Kong B
Expert Opin Ther Targets; 2021 Jan; 25(1):5-13. PubMed ID: 33246383
[TBL] [Abstract][Full Text] [Related]
19. An Immunological Glance on Pancreatic Ductal Adenocarcinoma.
Melzer MK; Arnold F; Stifter K; Zengerling F; Azoitei N; Seufferlein T; Bolenz C; Kleger A
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397303
[TBL] [Abstract][Full Text] [Related]
20. Uncovering key targets of success for immunotherapy in pancreatic cancer.
Pretta A; Lai E; Persano M; Donisi C; Pinna G; Cimbro E; Parrino A; Spanu D; Mariani S; Liscia N; Dubois M; Migliari M; Impera V; Saba G; Pusceddu V; Puzzoni M; Ziranu P; Scartozzi M
Expert Opin Ther Targets; 2021 Nov; 25(11):987-1005. PubMed ID: 34806517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
